GAMMAGARD LIQUID is indicated as a maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN). GAMMAGARD LIQUID for MMN is for intravenous use only.
![GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% logo.](/content/experience-fragments/takeda/gammagard/us/en/hcp/mmn/header---mmn/master/_jcr_content/root/container_1325140548/container_6852551/container/image.coreimg.svg/1755842420057/logo-gammagard-white.svg){kind=logo}
GAMMAGARD LIQUID for
Multifocal Motor Neuropathy (MMN) Treatment
1st & only FDA-approved IVIG treatment for adults with MMN
Evaluated in the largest clinical trial of MMN to date, GAMMAGARD LIQUID was assessed for improvement in muscle strength and disability.1
Help your patients living with MMN
MMN symptoms can get in the way of daily tasks like tying a shoelace, buttoning a coat, or even gripping a utensil to eat.2
GAMMAGARD LIQUID is the first and only FDA-approved IVIG treatment for adults with MMN.1 With assessed efficacy in improvement of muscle strength and reduced disability, GAMMAGARD LIQUID may help your patients with simple acts of self-care.1 In a 60-week clinical study with 44 adults with MMN, GAMMAGARD LIQUID was shown to improve or maintain grip strength and reduce disability compared to placebo.
FDA=Food and Drug Administration; MMN=Multifocal Motor Neuropathy.
Learn about GAMMAGARD LIQUID for MMN
Demonstrated efficacy
When considering treatment for adults with MMN, you may be interested in offering the only FDA-approved IVIG option. The safety and efficacy of GAMMAGARD LIQUID were evaluated in the largest controlled clinical trial for MMN to date.1 Review study design details and see the results.
Established safety profile
Of course, safety is always an important consideration when initiating and monitoring patients throughout the infusion experience. The safety profile for GAMMAGARD LIQUID was established in the largest controlled clinical trial (N=44 adults) for MMN to date.1,3
Early detection is important
MMN is a rare immune-mediated, progressive motor neuropathy. A diagnosis of MMN can be elusive, often presenting with symptoms similar to those of other neuropathies.4,5 However, early detection is important, as many MMN patients respond to treatment.4 Get an overview of MMN and when to consider it in your diagnostic workup.
Stay informed with product news and resources
Subscribe for emails about GAMMAGARD LIQUID.
References:
- GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10%. Prescribing Information. Takeda Pharmaceuticals U.S.A., Inc.; 2024.
- Sharrack B, Hughes R. The Guy’s Neurological Disability Scale (GNDS): a New Disability Measure for Multiple Sclerosis. Stockton Press; 1999:1352-4585.
- Hahn AF, Beydoun SR, Lawson V, et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. J Peripher Nerv Syst. 2013;18(4):321-330.
- Vlam L, van der Pol WL, Cats EA, et al. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol. 2012;8(1):45-58.
- Katirji B, Koontz D. Disorders of peripheral nerves. In: Daroff RB, Fenichel GM, Jankovic J, Mazziotta JC, eds. Bradley’s Neurology in Clinical Practice. Vol 2. 6th ed. Saunders Elsevier; 2012:1915-2015.